SCLERO.ORG
Search

Dr. Oliver Distler

ISN Medical Advisory Board

My research group is working in the field of molecular biology to identify molecular targets for therapy in systemic sclerosis.

My name is Dr. Oliver Distler and I am serving on the medical advisory board of ISN. I am heading the scleroderma outpatient clinic at the University of Zurich, Switzerland.

Next to my medical duties, my research group is working in the field of molecular biology to identify molecular targets for therapy in systemic sclerosis.

How did I get in contact with scleroderma as a medical speciality? This was more than twelve years ago, when the German scleroderma self help group provided research grants for young medical doctors to conduct research in scleroderma. Ever since then I have continued my research on scleroderma.

Department of Rheumatology
University Hospital Zurich
Gloriastr. 25
8091 Zürich
Tel ++41-44-255-2687
FAX: ++41-44-255-4415
Email: [email protected]

Related Links

Featuring: Scleroderma Experts at the University Hospital Zurich

Scleroderma Experts at the University Hospital Zurich. These experts diagnose and treat systemic sclerosis in adults. Posted 07/13/12.

Welcome Dr. Oliver Distler: ISN Medical Advisory Board

MicroRNA-29, a Key Regulator of Collagen Expression in Systemic Sclerosis. In systemic sclerosis, miR-29a directly regulates collagen expression at the post-transcriptional level, which is a novel aspect of the complex regulatory network of fibrosis. Arthritis and Rheumatism, Vol. 62, No. 6, June 2010, pp 1733-1743. (Also see: Scleroderma Treatments)

Dr. Oliver Distler: ISN Medical Advisory Board. I am heading the scleroderma outpatient clinic at the University of Zurich, Switzerland. Next to my medical duties, my research group is working in the field of molecular biology to identify molecular targets for therapy in systemic sclerosis. Posted 03-30-08.

Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. A body of evidence has accumulated illustrating that rheumatoid arthritis synovial fibroblasts are active drivers of joint destruction in rheumatoid arthritis. Ulf Müller-Ladner, Caroline Ospelt, Steffen Gay, Oliver Distler, and Thomas Pap, Arthritis Research & Therapy 2007, 9(6): 223. (Also see Rheumatoid Arthritis and Prof. Ulf Müller-Ladner, MD: ISN Medical Advisory Board)

Go to Doom, Sheryl
 
Recent Donors
See ISN News for recent donors, including memorials for
Patricia Ann Black, Gayle Hedlin, and Janet Paulmenn.
 

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

 
The most important thing in the world to know about scleroderma is sclero.org!
Donate Now
Copyright 1998-2016, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.